← Back to Search

Tranexamic Acid for Hip Fracture (TAHFT Trial)

Phase 3

Waitlist Available

Led By Gregory Tocks, DO

Research Sponsored by Lancaster General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Hip fracture location within the femoral neck, intertrochanteric, and subtrochanteric regions

Indication for one of the following surgical interventions: hemiarthroplasty, total hip replacement, sliding plate and screw fixation, or intramedullary fixation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

TAHFT Trial Summary

This trial will compare the effects of tranexamic acid (TXA) versus placebo on blood loss and transfusion requirements in patients over 60 years old who have undergone hip fracture surgery.

Who is the study for?

This trial is for people aged 65 or older who have a hip fracture in specific areas and need surgery like hemiarthroplasty, total hip replacement, or certain types of fixation. It's not for those with clotting disorders, recent strokes, heart attacks, deep vein thrombosis/pulmonary emboli, or allergies to Tranexamic Acid.Check my eligibility

What is being tested?

The study tests if giving Tranexamic Acid (TXA) before surgery helps geriatric patients with hip fractures compared to a placebo. Participants are randomly assigned to receive either TXA or placebo without knowing which one they get.See study design

What are the potential side effects?

Tranexamic Acid can cause side effects such as nausea, vomiting, diarrhea, and possibly increase the risk of blood clots. However, it's generally well-tolerated when used to reduce bleeding during surgeries.

TAHFT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My hip fracture is in the upper part of my thigh bone.

Select...

I am indicated for a specific type of hip surgery.

Select...

I am 65 years old or older.

TAHFT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Blood Transfusions

Secondary outcome measures

Complication Rate

Hospital Readmission

Mortality Rate

TAHFT Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: InterventionActive Control1 Intervention

100 cc normal saline with 1g of tranexamic acid in solution

Group II: PlaceboPlacebo Group1 Intervention

100 cc normal saline

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Lancaster General HospitalLead Sponsor

22 Previous Clinical Trials

3,392 Total Patients Enrolled

1 Trials studying Hip Fracture

Gregory Tocks, DOPrincipal InvestigatorPenn Medicine / Lancaster General Hospital

Media Library

Placebo Clinical Trial Eligibility Overview. Trial Name: NCT03923959 — Phase 3

Hip Fracture Research Study Groups: Intervention, Placebo

Hip Fracture Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT03923959 — Phase 3

Placebo 2023 Treatment Timeline for Medical Study. Trial Name: NCT03923959 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA given the go-ahead to this new method/drug/etc.?

"There is some evidence that the intervention being tested is effective, as well as numerous reports confirming its safety, so our team has given it a score of 3."

Answered by AI

What is the typical reason why a doctor would prescribe Intervention?

"Although hyperfibrinolysis is the primary use case, Intervention is also effective for treating other conditions like hemophilia, bleeding, and tooth extractions."

Answered by AI

Are new volunteers being sought for this experiment?

"The clinicaltrials.gov website indicates that this trial is not presently looking for participants. This particular trial was first posted on February 1st, 2020 and was last updated on October 25th, 2022. There are 455 other trials that are actively recruiting patients."

Answered by AI

Is Intervention a common medical procedure?

"At the moment, 69 clinical trials studying Intervention are ongoing. Among these, 29 are in Phase 3. Many of the studies for Intervention are based in Kansas City, Kansas; however, 305 locations across the globe are running trials for this treatment."

Answered by AI

Recent research and studies

European Journal of Cardio-Thoracic SurgeryJournal

Tranexamic Acid and Aprotinin in Low- and Intermediate-risk Cardiac Surgery: A Non-sponsored, Double-blind, Randomised, Placebo-controlled Trial☆

Later, Alexander F.L., Jacinta J. Maas, Frank H.M. Engbers, Michel I.M. Versteegh, Eline F. Bruggemans, Robert A.E. Dion, and Robert J.M. Klautz. 2009. “Tranexamic Acid and Aprotinin in Low- and Intermediate-risk Cardiac Surgery: A Non-sponsored, Double-blind, Randomised, Placebo-controlled Trial☆”. European Journal of Cardio-thoracic Surgery. Oxford University Press (OUP). doi:10.1016/j.ejcts.2008.11.038.

The Journal of ArthroplastyJournal

The Efficacy of Tranexamic Acid in Total Hip Arthroplasty: A Network Meta-analysis

Fillingham, Yale A., Dipak B. Ramkumar, David S. Jevsevar, Adolph J. Yates, Peter Shores, Kyle Mullen, Stefano A. Bini, et al.. 2018. “The Efficacy of Tranexamic Acid in Total Hip Arthroplasty: A Network Meta-analysis”. The Journal of Arthroplasty. Elsevier BV. doi:10.1016/j.arth.2018.06.023.

Acta Orthopaedica ScandinavicaJournal

Tranexamic Acid, Given at the End of the Operation, Does Not Reduce Postoperative Blood Loss in Hip Arthroplasty

Benoni, Göran, Stefan Lethagen, Paul Nilsson, and Hans Fredin. 2000. “Tranexamic Acid, Given at the End of the Operation, Does Not Reduce Postoperative Blood Loss in Hip Arthroplasty”. Acta Orthopaedica Scandinavica. Medical Journals Sweden AB. doi:10.1080/000164700317411834.

Journal of Bone and Joint SurgeryJournal